Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin-Reference-Cited by-同舟云学术

Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kawuma Aida N.¹^ORCID,Wasmann Roeland E.¹,Dooley Kelly E.²³^ORCID,Boffito Marta⁴,Maartens Gary¹^ORCID,Denti Paolo¹^ORCID

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

2. Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

3. Centre for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

4. Department of Infectious Diseases, Imperial College London, London, United Kingdom

Abstract

Dolutegravir-based regimens are recommended as first-line therapy for HIV in low- and middle-income countries where tuberculosis is the most common opportunistic infection. Concurrent HIV/tuberculosis treatment is challenging because of drug-drug interactions.

Funder

Pharmacometrics Africa NPC

Unitaid

ViiV Healthcare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00215-22

Reference29 articles.

1. WHO. 2019. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. WHO, Geneva, Switzerland.

2. Dolutegravir

3. In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

4. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

5. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple Infectious Syndrome: Pulmonary Tuberculosis and HIV in a Case of Pure Neuritic Leprosy With Underlying Diabetes Mellitus;Cureus;2024-08-04

2. Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial;Journal of the Pediatric Infectious Diseases Society;2024-07-27

3. Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions;Expert Review of Clinical Pharmacology;2024-06-04

4. Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin;Antimicrobial Agents and Chemotherapy;2023-11-15

5. Dolutegravir dosing with rifampicin – Authors' reply;The Lancet HIV;2023-10